News from the Danish Medicines Agency

  • Remdesivir for treatment of COVID-19 to continue in Denmark and Europe until further notice

    | 24 November 2020 |

    Remdesivir for the treatment of hospitalised COVID-19 patients will continue in Denmark and the rest of Europe, awaiting the collection of further data that will provide conclusive evidence on the medicine’s efficacy and safety.

  • Fourth contract ensuring access to a potential COVID-19 vaccine

    | 19 November 2020 |

    Denmark has entered into a fourth contract with a vaccine manufacturer that will ensure the delivery of vaccines for COVID-19; the contract is signed by the European Commission on behalf of the EU member states. The contract means that about 2 million people can be vaccinated against coronavirus, provided the vaccine is approved by the authorities.

  • EMA starts rolling review of corona vaccine from Moderna

    | 17 November 2020 |

    The European Medicines Agency, EMA, has started a rolling review of data from the clinical trials of a potential COVID-19 vaccine from the manufacturer Moderna. The EMA has previously started the same process for other potential vaccines from AstraZeneca and BioNTech/Pfizer.

  • Opens today: New Data Analytics Center is to give people better and safer medicines and medical devices

    | 16 November 2020 |

    Today, the Danish Medicines Agency officially opens its new Data Analytics Center (DAC), a center that is to translate information and data about medicines and medical devices into knowledge that will benefit the general public. Objective: Better and safer medicines and medical devices.

  • Opioid use in Denmark is decreasing

    | 04 November 2020 |

    Total sales of opioids have decreased by more than 20 per cent in the past four years, and there are now fewer Danes who use the most common type of opioid, tramadol. So reveals two new studies from the Danish Health Data Authority and the Danish Medicines Agency.